MicroRNA‑663b downregulation inhibits proliferation and induces apoptosis in bladder cancer cells by targeting TUSC2

Chen,Jianying; Song,Bo; Kong,Guangqi

doi:10.3892/mmr.2019.10023

MicroRNA‑663b downregulation inhibits proliferation and induces apoptosis in bladder cancer cells by targeting TUSC2

Authors:
- Jianying Chen
- Bo Song
- Guangqi Kong
View Affiliations

Affiliations: Urology Department, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, P.R. China
Published online on: March 14, 2019 https://doi.org/10.3892/mmr.2019.10023
Pages: 3896-3902

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the role and underlying molecular mechanism of microRNA‑663b (miR‑663b) in the tumorigenesis of bladder cancer. The miR‑663b expression in human bladder cancer tissues and cell lines was measured determined reverse transcription‑quantitative polymerase chain reaction. TargetScan was used to predict the potential targets of miR‑663b, and a dual‑luciferase reporter assay was performed to validate tumor suppressor candidate 2 (TUSC2) as a target of miR‑663b. Cell Counting Kit‑8 was used for cell viability analysis, and cell apoptosis was evaluated by flow cytometry. In addition, western blot analysis was performed to detect protein expression in current study. The findings suggested that miR‑663b was upregulated in bladder cancer tissues and cell lines compared with normal tissue and cells. TUSC2 was validated as a direct target of miR‑663b and was negatively regulated by miR‑663b. miR‑663b inhibition significantly reduced the viability of T24 cells, and T24 cell apoptosis was markedly induced. In addition, miR‑663b inhibition enhanced the expression levels of p53 and p21 in T24 cells. Furthermore, the changes caused by miR‑663b inhibitor in T24 cells were eliminated by TUSC2 gene silencing. In conclusion, inhibition of miR‑663b reduced viability and induced apoptosis in bladder cancer cells by targeting TUSC2. These findings provide a promising novel therapeutic target for bladder cancer treatment.

View Figures

View References

1	Swarup V and Rajeswari MR: Circulating (cell-free) nucleic acids-a promising, non-invasive tool for early detection of several human diseases. FEBS Lett. 581:795–799. 2007. View Article : Google Scholar : PubMed/NCBI
2	Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F: Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol. 71:96–108. 2017. View Article : Google Scholar : PubMed/NCBI
3	Moyer VA and U.S. Preventive Services Task Force: Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 155:246–251. 2011. View Article : Google Scholar : PubMed/NCBI
4	Griffiths TR and Action on Bladder Cancer: Current perspectives in bladder cancer management. Int J Clin Pract. 67:435–448. 2013. View Article : Google Scholar : PubMed/NCBI
5	Smith AB, Crowell K, Woods ME, Wallen EM, Pruthi RS, Nielsen ME and Lee CT: Functional outcomes following radical cystectomy in women with bladder cancer: A systematic review. Eur Urol Focus. 3:136–143. 2017. View Article : Google Scholar : PubMed/NCBI
6	Schulz GB, Grimm T, Buchner A, Jokisch F, Grabbert M, Schneevoigt BS, Kretschmer A, Stief CG and Karl A: Prognostic value of the preoperative platelet-to-leukocyte ratio for oncologic outcomes in patients undergoing radical cystectomy for bladder cancer. Clin Genitourin Cancer. 15:e915–e921. 2017. View Article : Google Scholar : PubMed/NCBI
7	Coleman EA and Boult C; American Geriatrics Society Health Care Systems Committee, : Improving the quality of transitional care for persons with complex care need. J Am Geriatr Soc. 51:556–557. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ambros V: microRNAs: Tiny regulators with great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
11	Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009. View Article : Google Scholar : PubMed/NCBI
12	Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T and Visakorpi T: MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol. 59:671–681. 2011. View Article : Google Scholar : PubMed/NCBI
13	Shi Z, Wei Q, Zhang M and She J: MicroRNAs in bladder cancer: Expression profiles, biological functions, regulation, and clinical implications. Crit Rev Eukaryot Gene Expr. 24:55–75. 2014. View Article : Google Scholar : PubMed/NCBI
14	Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, et al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
15	Du M, Shi D, Yuan L, Li P, Chu H, Qin C, Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. Sci Rep. 5:104372015. View Article : Google Scholar : PubMed/NCBI
16	Xin J, Zhang XK, Xin DY, Li XF, Sun DK, Ma YY and Tian LQ: FUS1 acts as a tumor-suppressor gene by upregulating miR-197 in human glioblastoma. Oncol Rep. 34:868–876. 2015. View Article : Google Scholar : PubMed/NCBI
17	Uzhachenko R, Shanker A, Yarbrough WG and Ivanova AV: Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity. Oncotarget. 6:20754–20772. 2015. View Article : Google Scholar : PubMed/NCBI
18	Li L, Yu C, Ren J, Ye S, Ou W, Wang Y, Yang W, Zhong G, Chen X, Shi H, et al: Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo. J Cancer Res Clin Oncol. 140:895–907. 2014. View Article : Google Scholar : PubMed/NCBI
19	Uzhachenko R, Ivanov SV, Yarbrough WG, Shanker A, Medzhitov R and Ivanova AV: Fus1/Tusc2 is a novel regulator of mitochondrial calcium handling, Ca2+-coupled mitochondrial processes, and Ca2+-dependent NFAT and NF-κB pathways in CD4+ T cells. Antioxid Redox Signal. 20:1533–1547. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lin J, Sun T, Ji L, Deng W, Roth J, Minna J and Arlinghaus R: Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: Inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene. 26:6989–6996. 2007. View Article : Google Scholar : PubMed/NCBI
21	Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wistuba I, Roth J and Pass HI: Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 8:912009. View Article : Google Scholar : PubMed/NCBI
22	Rimkus T, Sirkisoon S, Harrison A and Lo HW: Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers. Discov Med. 23:325–330. 2017.PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Shu Y, Ye W, Gu YL and Sun P: Blockade of miR-663b inhibits cell proliferation and induces apoptosis in osteosarcoma via regulating TP73 expression. Bratisl Lek Listy. 119:41–46. 2018.PubMed/NCBI
25	Rogers K and Chen X: Biogenesis, turnover, and mode of action of plant microRNAs. Plant Cell. 25:2383–2399. 2013. View Article : Google Scholar : PubMed/NCBI
26	Cho WC: MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
27	Yang X, Shi L, Yi C, Yang Y, Chang L and Song D: MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. Am J Cancer Res. 7:1738–1753. 2017.PubMed/NCBI
28	Luo H, Yang R, Li C, Tong Y, Fan L, Liu X and Xu C: MicroRNA-139-5p inhibits bladder cancer proliferation and self-renewal by targeting the Bmi1 oncogene. Tumour Biol. 39:10104283177184142017. View Article : Google Scholar : PubMed/NCBI
29	Wang W, Shen F and Wang C, Lu W, Wei J, Shang A and Wang C: MiR-1-3p inhibits the proliferation and invasion of bladder cancer cells by suppressing CCL2 expression. Tumour Biol. 39:10104283176983832017.PubMed/NCBI
30	Wu D, Niu X, Tao J, Li P, Lu Q, Xu A, Chen W and Wang Z: MicroRNA-379-5p plays a tumor-suppressive role in human bladder cancer growth and metastasis by directly targeting MDM2. Oncol Rep. 37:3502–3508. 2017. View Article : Google Scholar : PubMed/NCBI
31	Takai T, Yoshikawa Y, Inamoto T, Minami K, Taniguchi K, Sugito N, Kuranaga Y, Shinohara H, Kumazaki M, Tsujino T, et al: A novel combination rnai toward warburg effect by replacement with miR-145 and silencing of PTBP1 induces apoptotic cell death in bladder cancer cells. Int J Mol Sci. 18:E1792017. View Article : Google Scholar : PubMed/NCBI
32	Meng J, Majidi M, Fang B, Ji L, Bekele BN, Minna JD and Roth JA: The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner. PLoS One. 8:e770672013. View Article : Google Scholar : PubMed/NCBI
33	da Costa Prando E, Cavalli LR and Rainho CA: Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines. Epigenetics. 6:1413–1424. 2011. View Article : Google Scholar : PubMed/NCBI